While COVID-19 has taken center stage for the past year, there remains a huge need for advance testing, treatment options and cures for other diseases. That points toward personalized medicine and next-generation genomic sequencing (NGS) solutions.

Seven companies IPO'd in two days this week. Meanwhile, Dermavant postponed the IPO that was due Thursday.